Takeda, PE firm launch GI-focused pharmaceutical company — 3 insights

Takeda and Frazier Healthcare Partners launched Phathom Pharmaceuticals to develop gastrointestinal treatments.

What you should know:

1. Phathom will develop and commercialize Takeda's potassium competitive acid blocker, vonoprazan, in the U.S., Europe and Canada.

2. Frazier led a $90 million financing round supported by several other investors.

3. Phathom then took out a $50 million loan through Silicon Valley Bank to support developmental efforts.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

ASC_GI_300x250

Featured Webinars

Featured Whitepapers

Featured Podcast